...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer investigation >Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer (see comments)
【24h】

Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer (see comments)

机译：成人晚期难治性癌症的每周长春瑞滨联合紫杉醇每周一期研究（见评论）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Vinorelbine and paclitaxel are highly active antineoplastic agents. Preclinical data indicate a potential for antitumor synergy for a number of common tumor types when they are combined. We investigated a novel weekly schedule of both agents. Eighteen patients with advanced cancer were entered onto this phase I trial. Vinorelbine and paclitaxel were given weekly in combination for 6 consecutive weeks, followed by a 2-week break. Sequential cohorts of patients were treated at two dose levels: vinorelbine 22.5 mg/m2 followed by paclitaxel 40 mg/m2 and vinorelbine 22.5 mg/m2 followed by paclitaxel 60 mg/m2. Ten patients completed at least one 8-week course of therapy. Neutropenic myelosuppression was dose limiting at level II. Neurotoxicity was not dose limiting. Objective responses were seen in patients with esophageal, lung, and breast cancer and suggest that this is an active regimen worthy of further investigation in selected diseases. Phase II trials of this regimen are in progress.
机译：长春瑞滨和紫杉醇是高活性抗肿瘤药。临床前数据表明，将多种常见肿瘤合并后可能具有抗肿瘤协同作用。我们调查了这两个代理商的新颖每周时间表。 18名晚期癌症患者进入了这一I期试验。每周联合给予长春瑞滨和紫杉醇，连续6周，然后休息2周。依次对患者进行了两个剂量水平的治疗：长春瑞滨22.5 mg / m2，然后是紫杉醇40 mg / m2;长春瑞滨22.5 mg / m2，然后是紫杉醇60 mg / m2。 10名患者完成了至少一个8周的疗程。中性粒细胞减少是在II级剂量限制。神经毒性不是剂量限制的。在食道癌，肺癌和乳腺癌患者中观察到客观反应，这表明这是一种值得在某些疾病中进一步研究的有效方案。该方案的II期试验正在进行中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号